Analysts Set Sanofi SA (SNY) PT at $49.50

Shares of Sanofi SA (NYSE:SNY) have received an average rating of “Hold” from the seventeen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $49.50.

A number of equities research analysts recently commented on SNY shares. Citigroup raised shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. Bank of America raised shares of Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Monday, September 10th. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Argus boosted their price objective on Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, August 24th. Finally, Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st.

Shares of SNY stock traded up $0.06 on Tuesday, reaching $43.77. 19,091 shares of the company were exchanged, compared to its average volume of 858,876. The stock has a market capitalization of $110.71 billion, a PE ratio of 13.99, a price-to-earnings-growth ratio of 2.50 and a beta of 0.71. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. Sanofi has a one year low of $37.43 and a one year high of $45.86.

Sanofi (NYSE:SNY) last released its quarterly earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. The company had revenue of $9.39 billion for the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm’s revenue was up 1.5% on a year-over-year basis. During the same period last year, the firm earned $1.71 earnings per share. On average, analysts anticipate that Sanofi will post 3.09 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Teachers Advisors LLC bought a new position in shares of Sanofi in the 3rd quarter worth $31,557,000. FMR LLC increased its holdings in shares of Sanofi by 7.5% in the 3rd quarter. FMR LLC now owns 8,527,983 shares of the company’s stock worth $380,945,000 after buying an additional 595,125 shares during the last quarter. TIAA CREF Investment Management LLC bought a new position in shares of Sanofi in the 3rd quarter worth $26,081,000. Tocqueville Asset Management L.P. increased its holdings in shares of Sanofi by 555.7% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 608,836 shares of the company’s stock worth $50,014,000 after buying an additional 515,986 shares during the last quarter. Finally, Sofinnova Ventures Inc bought a new position in Sanofi in the third quarter valued at $18,438,000. Institutional investors and hedge funds own 7.06% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Why is the conference call important?

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply